Revolution Medicines, Inc. (RVMD)
Nasdaq: RVMD · Biological Products, (No Diagnostic Substances) · Redwood City, CA · filing with the SEC since 2016
Who owns Revolution Medicines, Inc.
As filed with the SECHolders of 5% or more
5
Dapice Joshua J. holds 7.5% of Common Stock, par value $0.0001 per share (the "Shares"), as its SCHEDULE 13G/A filed Feb 9, 2026 says.
Directors and officers
16
report now, of 23 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 9, 2026 · Common Stock, par value $0.0001 per share (the "Shares") · 7.9% in May 15, 2025
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.0001 per share (the "Shares")
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock · 4.5% in Jul 17, 2025
Baker Bros. Advisors LP
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 4.9% in Feb 17, 2026
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G · filed Aug 13, 2026 · Common Stock · 4.9% in May 15, 2026
Fmr LLC
SCHEDULE 13G · filed Nov 5, 2025 · COMMON STOCK · reported falling below 5%
Wellington Management Group LLP
SCHEDULE 13G/A · filed Feb 10, 2026 · Common Stock · reported falling below 5%, from 5.5% in Aug 12, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What RVMD reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
EQRx Acquisition
A company bought · acquisition · owns, named in the 10-K filed Feb 25, 2026
6 subsidiaries in 4 countries, from the list filed with the 10-K filed Feb 25, 2026.
Insider tradesForm 4
157sales
0purchases
156sales on a scheduled plan
12people selling
$151Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 43 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Goldsmith Mark A | President and Chief Executive Officer | 42 | $54.1M | 42 | 0 | $0 |
| Horn Margaret A | Chief Operating Officer | 16 | $25.3M | 16 | 0 | $0 |
| Kelsey Stephen Michael | Senior Advisor to the Chief Executive Officer | 13 | $21.3M | 13 | 0 | $0 |
| Kim Lorence H. | director | 14 | $15.0M | 14 | 0 | $0 |
| Cislini Jeff | SVP & General Counsel | 15 | $14.6M | 15 | 0 | $0 |
| Mancini Anthony | See Remarks | 24 | $10.4M | 23 | 0 | $0 |
| Anders Jack | Chief Financial Officer | 11 | $6.5M | 11 | 0 | $0 |
| Anderson Elizabeth M | director | 5 | $2.0M | 5 | 0 | $0 |
| Sandler Alan B. | Chief Development Officer | 7 | $1.3M | 7 | 0 | $0 |
| Patel Sushil | director | 9 | $1.0M | 9 | 0 | $0 |
| Wei Lin | Chief Medical Officer | 1 | $200,000 | 1 | 0 | $0 |
| Wang Xiaolin | EVP, Clinical Development | 1 | $200,000 | 1 | 0 | $0 |